Retatrutide UK Availability 2026 What Is It and When Will It Launch?
Retatrutide is one of the most talked about weight loss injections right now, and for good reason. Made by Eli Lilly, it is a once weekly injection that works on three different hormones in the body at the same time, which is why it is called a triple agonist. This is different from older drugs like Wegovy and Mounjaro, which only target one or two hormones each.
Early trial results have shown very strong weight loss numbers, with some people losing close to a third of their body weight during testing. This has made retatrutide one of the most closely watched medicines in the obesity treatment space, with doctors and patients across the UK asking when it might become available. Right now, retatrutide is still being tested and is not approved anywhere in the world, including the UK. This guide explains what it is, how it works, and when it might realistically launch.
Is Retatrutide Approved in the UK Yet?
No. Retatrutide is not approved in the UK. It is still being tested in clinical trials, and it has not been given a licence by the MHRA, the body that decides which medicines can be sold and prescribed here. Because of this, no UK pharmacy, doctor, or clinic can legally give it to you, whether through the NHS or privately. The only lawful way to get it right now is by joining an approved clinical trial. Anything sold online under the name “retatrutide” is not a real, licensed medicine, and it could be unsafe.
Quick Facts at a Glance
Retatrutide is made by Eli Lilly. It is still in Phase 3 trials. It has no MHRA approval. There is no confirmed UK launch date, either privately or on the NHS. Trial results so far show strong weight loss, but full safety data is still being collected.
What Is Retatrutide?
Retatrutide is a new weight loss injection that is still being tested. It is given once a week, similar to Wegovy and Mounjaro, but it works in a slightly different way. Most weight loss injections target one or two hormones in the body. Retatrutide targets three at once, which is why doctors call it a “triple agonist.”
The three hormones it acts on are GLP-1, GIP, and glucagon. GLP-1 helps you feel full and eat less. GIP helps control blood sugar and may help the body use fat better. Glucagon is the new addition compared to older drugs, and it may help the body burn more energy. Semaglutide, the drug in Wegovy, only works on GLP-1. Tirzepatide, the drug in Mounjaro, works on GLP-1 and GIP. Retatrutide adds the third pathway, which is thought to be why early trial results have shown such large weight loss numbers.
Is Retatrutide Available in the UK Right Now?
Retatrutide is not available in the UK today. It is what is known as an investigational medicine, meaning it is still going through testing and has not been reviewed and approved by any regulator, including the MHRA, the FDA in America, or the EMA in Europe.
Because it has no licence, it cannot be prescribed on the NHS. It also cannot be prescribed privately by a UK doctor, and no registered pharmacy is allowed to sell it. The only legal way for someone in the UK to receive retatrutide at the moment is by taking part in an approved clinical trial run by Eli Lilly. You can search for active trials through services like NIHR Be Part of Research. Simply wanting to try the drug is not enough to join a trial, since each study has its own strict entry rules.
Retatrutide Clinical Trial Results (TRIUMPH Programme)
Retatrutide is being tested through a large group of studies called the TRIUMPH programme. The first major Phase 3 results, from a trial called TRIUMPH-1, were released in 2026 and looked at adults with obesity or excess weight who did not have diabetes.
People taking the highest dose, 12 mg, lost close to 28 percent of their body weight on average after 80 weeks of treatment. Those on the 9 mg dose lost around 26 percent, and those on the lower 4 mg dose lost around 19 percent. People taking a placebo, which has no active medicine, lost only around 2 percent. Nearly half of the people on the highest dose lost at least 30 percent of their starting body weight, a result that is closer to what is normally seen after weight loss surgery than after an injection. Earlier Phase 2 trials, published a few years before this, first showed that retatrutide could produce this kind of strong weight loss, and those early results are part of why the drug has attracted so much attention.
Side Effects and Safety Profile
Like other weight loss injections in this family, retatrutide causes stomach related side effects for many people, especially when starting treatment or increasing the dose.
The most common problems reported in trials were nausea, diarrhoea, constipation, and vomiting. These affected a large share of people taking the drug, and they tended to be more common at higher doses. Most cases were mild to moderate and improved over time, though some people stopped treatment because the side effects were too uncomfortable to continue.
A newer side effect showed up in later trials that had not been seen as often with older drugs. Some people reported unusual or unpleasant skin sensations, sometimes described as tingling or discomfort under the skin. This became more common at higher doses. Because retatrutide is still new, doctors do not yet have long term safety information the way they do for older, approved medicines. Things like effects on the heart, the pancreas, and general health over many years are still being studied, and this is one of the main reasons regulators have not approved it yet.
When Will Retatrutide Launch in the UK? (Estimated Timeline)
Nobody can give an exact launch date yet, but the general path is becoming clearer as more trial results come in.
Through 2026, the remaining Phase 3 trials are expected to finish and report their results. After that, Eli Lilly is expected to apply for approval from regulators, likely in late 2026 or 2027. If the MHRA approves the drug, this could open the door to private prescriptions in the UK sometime in 2027 or 2028. NHS access would take longer, since it also needs a separate review from NICE, the body that decides whether a medicine offers good value for the NHS to fund. Based on how similar drugs have been handled before, most experts expect NHS availability from 2028 at the earliest, and this could shift depending on how quickly trials and reviews are completed.
Retatrutide vs Mounjaro vs Wegovy
People often want to know how retatrutide compares to the weight loss injections that are already available. Mounjaro and Wegovy are both licensed and can be prescribed in the UK today, while retatrutide cannot be prescribed at all yet.
In terms of results, trials suggest retatrutide may produce stronger average weight loss than either Mounjaro or Wegovy, though these results come from separate studies rather than a direct head to head comparison, so it is not a completely fair comparison yet. A trial comparing retatrutide directly against tirzepatide, the drug in Mounjaro, is underway, but results are not out yet. In terms of how they work, Wegovy targets one hormone, Mounjaro targets two, and retatrutide targets three. For now, if you are looking for a weight loss injection you can actually access, Mounjaro and Wegovy remain the only proven, licensed options in the UK.
Warning: Fake and Unlicensed Retatrutide in the UK
Because retatrutide has become well known through news coverage, unlicensed versions are already being sold online and on social media, often labelled as research chemicals to get around medicine laws. These products are not tested, not regulated, and not safe to assume are genuine.
The MHRA has already raided several illegal production sites in the UK and seized thousands of unlicensed pens and vials claiming to be retatrutide or tirzepatide. Because these products are made outside any regulated factory, there is no way to know what is really inside them or whether they are safe to inject.
If you notice symptoms such as ongoing vomiting, severe stomach pain, yellowing of the skin or eyes, swelling of the face or throat, or difficulty breathing after using an unlicensed product, seek urgent medical help straight away. You can also report a suspected bad reaction through the MHRA Yellow Card scheme, and report suspicious sellers through the MHRA’s FakeMeds service.
Licensed Weight Loss Alternatives Available in the UK Today
While retatrutide is still being tested, there are already effective, licensed treatments available in the UK for people who qualify. Mounjaro, which contains tirzepatide, and Wegovy, which contains semaglutide, are both approved and can be prescribed by a doctor or specialist weight management service. Saxenda, an older daily injection, is also still available for some patients. NHS weight management services can also offer support that combines medicine with diet and lifestyle changes for people who meet the eligibility criteria. Speaking to a GP or pharmacist is the safest way to find out which option might suit you.
Frequently Asked Questions
Can I get retatrutide on private prescription in 2026?
No. Retatrutide has no licence yet, so no UK doctor or clinic can legally prescribe it privately in 2026.
Is retatrutide better than Mounjaro?
Early trial results suggest it may produce stronger weight loss, but there is no direct comparison trial finished yet, so this is not fully proven.
How much will retatrutide cost in the UK?
There is no confirmed price yet, since the drug has not been approved or launched anywhere in the world.
Can I join a retatrutide clinical trial in the UK?
Yes, this is possible if you meet the entry requirements for an active study. You can check services like NIHR Be Part of Research or ClinicalTrials.gov for current trials.
Is buying retatrutide online illegal in the UK?
Selling unlicensed retatrutide as a medicine is illegal, and buying it carries real safety risks since there is no way to confirm what the product actually contains.
